RecruitingPhase 3NCT06623422
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Studying Autosomal dominant multiple pterygium syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Pembrolizumab(biological)
- Enrollment
- 680 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2038
Study locations (30)
- Banner MD Anderson Cancer Center ( Site 0181), Gilbert, Arizona, United States
- The University of Arizona Cancer Center - North Campus ( Site 0163), Tucson, Arizona, United States
- Providence St. Jude Medical Center ( Site 0106), Fullerton, California, United States
- VA Long Beach Healthcare System ( Site 0199), Long Beach, California, United States
- USC Norris Comprehensive Cancer Center ( Site 0205), Los Angeles, California, United States
- UCSF Medical Center at Mission Bay ( Site 0178), San Francisco, California, United States
- University of Colorado Anschutz Medical Campus ( Site 0151), Aurora, Colorado, United States
- UCHealth Memorial Hospital Central ( Site 0125), Colorado Springs, Colorado, United States
- Banner MD Anderson Cancer Center at North Colorado Medical Center ( Site 0207), Greeley, Colorado, United States
- Centura Health - St. Anthony North Health Campus ( Site 0189), Westminster, Colorado, United States
- Yale University School of Medicine ( Site 0201), New Haven, Connecticut, United States
- Eastern CT Hematology & Oncology Associates ( Site 0202), Norwich, Connecticut, United States
- The Oncology Institute of Hope and Innovation - Fort Lauderdale ( Site 0156), Fort Lauderdale, Florida, United States
- Miami Cancer Institute at Baptist Health, Inc. ( Site 0214), Miami, Florida, United States
- Beacon Cancer Care ( Site 0127), Post Falls, Idaho, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
ModernaTX, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06623422 on ClinicalTrials.govOther trials for Autosomal dominant multiple pterygium syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06941012Validation of α-synuclein Modifications in Parkinson's dIsoRder EvolutionCasa di Cura IGEA
- RECRUITINGNCT06949670Alpha-Synuclein PET/CT in Various α-Syn-Related DiseaseTianjin Medical University
- RECRUITINGPHASE2NCT05281003Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)Fudan University
- ACTIVE NOT RECRUITINGPHASE1NCT05382325A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)Merck Sharp & Dohme LLC
- RECRUITINGNCT07533799The Swedish BioFINDER Sleep StudySkane University Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04995523A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLCAstraZeneca
- RECRUITINGPHASE1, PHASE2NCT04938817Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)Merck Sharp & Dohme LLC
- RECRUITINGNCT04724941Prodromal Alpha-Synuclein Screening in Parkinson's Disease StudyUniversity Hospital Schleswig-Holstein
See all trials for Autosomal dominant multiple pterygium syndrome →